Multikinase Inhibitors Across the Board - prIME Oncology
Expert Review
Expert Review

Multikinase Inhibitors Across the Board

Novel Treatment Approaches in Gastrointestinal Cancers, Glioblastoma, and Sarcoma

Not a member of My prIME? Join now for instant access.

Watch a comprehensive, video-based review from leading experts in the field and download slides on the current and potential future role of multikinase inhibitors (MKI) in gastrointestinal cancers, glioblastoma, and sarcoma.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

1.25 AMA PRA Category 1 Credit(s)

Release Date

Release Date

Apr 30, 2019

Expiration Date

Apr 30, 2020

  • Axel Grothey, MDWest Cancer Center
    Memphis, Tennessee, United States
  • Giuseppe Lombardi, MDIstituto Oncologico Veneto
    Padova, Italy
  • Olivier Mir, MD, PhD, MPHInstitut Gustave Roussy
    University of Paris-Sud
    Villejuif, France
  • MKIs: Overview
  • MKIs in colorectal cancer
  • MKIs in hepatobiliary carcinoma
  • MKIs in GIST/sarcoma
  • MKIs in glioblastoma

This educational activity is designed for oncologists and other healthcare professionals involved/interested in the management of patients with gastrointestinal cancers, glioblastoma, and sarcoma.

After successful completion of this educational activity, participants should be able to:

  • Discuss the role of MKIs in the treatment of various tumor types, including gastrointestinal cancers, recurrent advanced cholangiocarcinoma, glioblastoma, and sarcoma
  • Implement treatment plans using multikinase inhibition in metastatic colorectal cancer (CRC), hepatocellular carcinoma (HCC), and sarcoma
  • Analyze efficacy and safety data with MKI in gastrointestinal cancers, glioblastoma, and sarcoma

This educational activity is supported by a grant from Bayer HealthCare Pharmaceuticals, Inc.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database and in your My prIME account. You can download your certificate as needed. Technical requirements may be found under the Terms of Use.

Estimated time to complete activity: 1.25 hours

To contact Postgraduate Institute for Medicine, please visit www.pimed.com.

Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Grothey has disclosed that he has received consulting fees from Array, Bayer Healthcare Pharmaceuticals, Bristol-Myers Squibb, Daiichi, Eisai, and Genentech. He has also performed contracted research for Array, Bayer Healthcare Pharmaceuticals, Eisai, and Genentech. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Lombardi has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Mir has disclosed that he has received consulting fees from Ipsen, Lundbeck, Pfizer, Roche, and Servier. He has also received fees for non–CME/CE services from Eli-Lilly, Janssen, Roche, and Vifor. He has performed contracted research for Blueprint Medicines. He has ownership interest (less than 5%) in Amplitude Surgical and Transgene. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

Postgraduate Institute for Medicine planners and managers have disclosed no relevant financial relationships.

The employees of prIME Oncology have disclosed:

  • Angela Zimmermann, PhD (scientific content manager) – worked on non-CME certified projects in the last 12 months supported by AstraZeneca, Merck, Novartis, and Pfizer
  • Susan McKinney – no relevant financial relationships
  • Ronald Viggiani, MD (medical director) – worked on non-CME certified projects in the last 12 months supported by Pfizer

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.